(Q35143277)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Experimental vaccines against measles in a world of changing epidemiology (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Mike M Pütz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Fabienne B Bouche

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

Claude P Muller

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 May 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

International Journal for Parasitology

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

525-545

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12782053%20AND%20SRC:MED&resulttype=core&format=json

Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Intracellular processing, glycosylation, and cell-surface expression of the measles virus fusion protein (F) encoded by a recombinant adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Loss of maternally-acquired measles antibody during infancy in Ilorin, Nigeria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Neonatal and early life immune responses to various forms of vaccine antigens qualitatively differ from adult responses: predominance of a Th2-biased pattern which persists after adult boosting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles virus hemagglutinin induces an Ld-restricted CD8+ cytotoxic T lymphocyte response to two specific epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

First 5 years of measles elimination in southern Africa: 1996-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A simplified immunoassay based on measles virus recombinant hemagglutinin protein for testing the immune status of vaccinees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Neutralising immunogenicity of a polyepitope antigen expressed in a transgenic food plant: a novel antigen to protect against measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Efficacy of individual measles virus structural proteins in the protection of rats from measles encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

The effect of dose and strain of live attenuated measles vaccines on serological responses in young infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Alternative routes of measles immunization: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles elimination: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Loss of maternal measles antibody during infancy in an African city

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Estimated susceptibility to asymptomatic secondary immune response against measles in late convalescent and vaccinated persons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Maternal measles antibody decay in rural Bangladeshi infants--implications for vaccination schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Placental antibody transfer: influence of maternal HIV infection and placental malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Enhanced antigenicity of a four-contact-residue epitope of the measles virus hemagglutinin protein by phage display libraries: evidence of a helical structure in the putative active site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Passive immunity against measles during the first 8 months of life of infants born to vaccinated mothers or to mothers who sustained measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles virus fusion protein presented in an immune-stimulating complex (iscom) induces haemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized wit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

New strategies for closing the gap of measles susceptibility in infants: towards vaccines compatible with current vaccination schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

The molecular basis of virus crossreactivity and neutralisation after immunisation with optimised chimeric peptides mimicking a putative helical epitope of the measles virus hemagglutinin protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A hemagglutinin-derived peptide-vaccine ignored by virus-neutralizing passive antibodies, protects against murine measles encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Neutralization of measles virus wild-type isolates after immunization with a synthetic peptide vaccine which is not recognized by neutralizing passive antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Propagation in tissue cultures of cytopathogenic agents from patients with measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Mucosal and systemic immune responses to measles virus haemagglutinin in mice immunized with a recombinant vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Class I-restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Recombinant bacille Calmette-Guérin priming against measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunization of mice with plasmid DNA expressing the measles virus nucleoprotein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Oral or parenteral administration of replication-deficient adenoviruses expressing the measles virus haemagglutinin and fusion proteins: protective immune responses in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Antibodies to a new linear site at the topographical or functional interface between the haemagglutinin and fusion proteins protect against measles encephalitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Pathogenesis of respiratory syncytial virus vaccine-augmented pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

C3d enhancement of neutralizing antibodies to measles hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Pathogenesis of measles virus infection: an hypothesis for altered immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Molecular epidemiology of Nigerian and Ghanaian measles virus isolates reveals a genotype circulating widely in western and central Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Genetic variability of measles viruses circulating in the Benelux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protection against measles virus-induced encephalitis by antibodies from mice immunized intranasally with a synthetic peptide immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Hybridomas secreting monoclonal antibody to Toxoplasma gondii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Studies on an attenuated measles-virus vaccine. VIII. General summary and evaluation of the results of vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Use of Edmonston attenuated measles strain. A summary of three years' experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Resistance of recent measles virus wild-type isolates to antibody-mediated neutralization by vaccinees with antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Further-attenuated measles vaccine: characteristics and use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Further attenuated live measles vaccines: The need for revised recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Maternally derived measles immunity in era of vaccine-protected mothers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Dry powder inhalation as a potential delivery method for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A powder formulation of measles vaccine for aerosol delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A population-based study of measles, mumps, and rubella vaccination and autism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Evolution of maternofetal transport of immunoglobulins during human pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Characterization of a secreted form of measles virus haemagglutinin expressed from a vaccinia virus recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

The role of secondary vaccine failures in measles outbreaks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Experimental measles. I. Pathogenesis in the normal and the immunized host.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles vaccine efficacy determined from secondary attack rates during a severe epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Persistence of Measles Virus and Depression of Antibody Formation in Patients with Giant-Cell Pneumonia after Measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Detection of measles vaccine in the throat of a vaccinated child.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Implications of the human immunodeficiency virus epidemic for control and eradication of measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles elimination: old and new challenges?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Secondary immune responses in parents of children with recent measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Approaches to development of microencapsulated form of the live measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Studying experimental measles virus vaccines in the presence of maternal antibodies in the cotton rat model (Sigmodon hispidus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protective immunity, but suppressed immune responses to third party antigens are generated in cotton rats during measles virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles virus-induced immunosuppression in cotton rats is associated with cell cycle retardation in uninfected lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Differences in the Appearance of Antibodies to Structural Components of Measles Virus after Immunization with Inactivated and Live Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunization of asymptomatic HIV-infected children with measles vaccine: assessment of risks and benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Immunopathogenesis of vaccine-enhanced RSV disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Vaccine strategies to overcome maternal antibody mediated inhibition of measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Increased susceptibility to measles in infants in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Fine specificity of the antibody response to a synthetic peptide from the fusion protein and protection against measles virus-induced encephalitis in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A role for immune complexes in enhanced respiratory syncytial virus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Functional fine-mapping and molecular modeling of a conserved loop epitope of the measles virus hemagglutinin protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

The rationale of a peptide-conjugate vaccine against measles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

DNA vaccination with both the haemagglutinin and fusion proteins but not the nucleocapsid protein protects against experimental measles virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Vaccination in the neonatal period and early infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Salmonella vaccines secreting measles virus epitopes induce protective immune responses against measles virus encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

MVA: a cuckoo in the vaccine nest?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Priming of measles virus-specific humoral- and cellular-immune responses in macaques by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Enteric administration of a live attenuated measles vaccine does not induce protective immunity in a macaque model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Longevity of neutralizing antibody levels in macaques vaccinated with Quil A-adjuvanted measles vaccine candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Vaccination against measles: a neverending story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

New use of BCG for recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Nonreplicating vaccinia vector efficiently expresses recombinant genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Recombinant fowlpox virus inducing protective immunity in non-avian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protective immunity against avian influenza induced by a fowlpox virus recombinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Differential antigenicity of recombinant polyepitope-antigens based on loop- and helix-forming B and T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

DNA immunization: effect of secretion of DNA-expressed hemagglutinins on antibody responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Genotypic and antigenic characterization of hemagglutinin proteins of African measles virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Viral replication and development of specific immunity in macaques after infection with different measles virus strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Sero-epidemiology of measles antibodies in the Netherlands, a cross-sectional study in a national sample and in communities with low vaccine coverage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Intracellular processing and presentation of T cell epitopes, expressed by recombinant Escherichia coli and Salmonella typhimurium, to human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Effective synthetic peptide vaccine for foot-and-mouth disease in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Production of measles nucleoprotein in different expression systems and its use as a diagnostic reagent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles vaccines, new developments and immunization strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles virus replication in lungs of hispid cotton rats after intranasal inoculation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Replication of clinical measles virus strains in hispid cotton rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Use of cotton rats for preclinical evaluation of measles vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Early studies on DNA-based immunizations for measles virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Measles immunization. Successes and failures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Recombinant bacille Calmette-Guérin expressing the measles virus nucleoprotein protects infant rhesus macaques from measles virus pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

Protection against measles virus encephalitis by monoclonal antibodies binding to a cystine loop domain of the H protein mimicked by peptides which are not recognized by maternal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

High-level eucaryotic in vivo expression of biologically active measles virus hemagglutinin by using an adenovirus type 5 helper-free vector system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021

Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-7519%2803%2900062-6

7 January 2021